Gaucher disease (GD) is a prevalent lysosomal storage disorder (LSD) that significantly impacts individuals’ lives. However, the exorbitant prices of GD medications pose a major hurdle in ensuring widespread availability and affordability of treatment in India. The country heavily relies on imported medications, leading to high costs and limited access for many patients. This article aims to address this issue by advocating for the establishment of indigenous manufacturing capabilities for GD medicines in India. Through an examination of the current landscape of GD treatment, including the availability, affordability, and challenges associated with imported medications, this article highlights the urgent need for localized production. By focusing on the potential benefits of indigenous manufacturing, such as reduced costs, increased accessibility, and enhanced availability, this research aims to provide insights and recommendations to policymakers, healthcare professionals, and relevant stakeholders. The findings underscore the importance of developing domestic manufacturing capabilities to address the affordability and accessibility challenges faced by GD patients in India. The research also emphasizes the potential positive impact on the healthcare system, the pharmaceutical industry, and the overall well-being of individuals with GD. Ultimately, this article seeks to stimulate discussions and actions towards creating a sustainable framework for indigenous manufacturing of GD medicines, thereby improving the lives of those affected by this rare and debilitating condition.

戈谢病 (GD) 是一种常见的溶酶体贮积症 (LSD)，严重影响个人的生活。然而，GD 药物的高昂价格构成了确保印度广泛获得和负担得起治疗的主要障碍。该国严重依赖进口药物，导致费用高昂且许多患者获得药物的机会有限。本文旨在通过倡导在印度建立 GD 药物的本土制造能力来解决这个问题。本文通过考察 GD 治疗的现状，包括可用性、可负担性以及与进口药物相关的挑战，强调了本地化生产的迫切需要。通过关注本土制造的潜在好处，例如降低成本、增加可及性和提高可用性，本研究旨在为政策制定者、医疗保健专业人员和相关利益相关者提供见解和建议。研究结果强调了发展国内制造能力以解决印度 GD 患者面临的负担能力和可及性挑战的重要性。该研究还强调了对医疗保健系统、制药行业以及 GD 患者整体福祉的潜在积极影响。最终，本文旨在激发讨论和行动，为本地 GD 药物生产创建可持续框架，从而改善受这种罕见且令人衰弱的疾病影响的人们的生活。